Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial - Ella, Raches; Reddy, Siddarth; Blackwelder, William; Potdar, Varsha; Yadav, Pragya; Sarangi, Vamshi; Aileni, Vinay K; Rai, Sanjay; Reddy, Prabhakar; Verma, Savita; Singh, Chandramani; Redkar, Sagar; et al. (The Lancet (British edition), 2021)
Keywords: Adjudication; Adjuvants, Immunologic; Adult; Adults; Adverse events; Anaphylaxis; Antigens; Asymptomatic; Chronic conditions; Chronic illnesses; Clinical significance; Clinical trials; Committees; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 Nucleic Acid Testing; COVID-19 vaccines; COVID-19 Vaccines - immunology; Deactivation; Dosage; Double-Blind Method; Double-blind studies; Female; Health services; Humans; Immunization; Immunogenicity; Immunogenicity, Vaccine; Immunology; Immunosuppressive agents; India; Male; Medical research; Pandemics; Placebos; Polymerase chain reaction; Population studies; Proteins; Randomization; Safety; Severe acute respiratory syndrome coronavirus 2; Toll-like receptors; Vaccine Efficacy; Vaccines; Vaccines, Inactivated - immunology; Viral diseases; Virions; India